Pre-made Samrotamab benchmark antibody ( Whole mAb ADC, anti-LRRC15 therapeutic antibody, Anti-LIB Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Samrotamab biosimilar, Whole mAb ADC, Anti-LRRC15 Antibody: Anti-LIB therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Telisotuzumab vedotin (ABBV-399) is an antibody drug conjugate (ADC) targeting cMet that is being investigated to treat non-small cell lung cancer.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-505-1mg	1mg	4635
GMP-Bios-ab-505-10mg	10mg	Inquiry
GMP-Bios-ab-505-100mg	100mg	Inquiry
GMP-Bios-ab-505-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Samrotamab biosimilar, Whole mAb ADC, Anti-LRRC15 Antibody: Anti-LIB therapeutic antibody
INN Name	Samrotamab
Target	LRRC15
Format	Whole mAb ADC
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2017
Year Recommended	2018
Companies	AbbVie
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Solid tumours
Development Tech	na